We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
1826-P: Comparison of OGTT-Model Measures with the Hyperglycemic Clamp in Youth and Adults with IGT or Early Type 2 Diabetes (DM).
- Authors
UTZSCHNEIDER, KRISTINA; MARI, ANDREA; TRIPPUTI, MARK; MATHER, KIEREN J.; NADEAU, KRISTEN J.; EDELSTEIN, SHARON; HANNON, TAMARA S.; ARSLANIAN, SILVA A.; CREE-GREEN, MELANIE; BUCHANAN, THOMAS A.; CAPRIO, SONIA; KAHN, STEVEN E.
- Abstract
The Restoring Insulin Secretion (RISE) Study found that compared to adults (A), youth (Y) with early DM (33 Y, 104 A) or IGT (53 Y, 250 A) have higher insulin and C-peptide responses, even after adjusting for differences in insulin sensitivity. To better understand these differences, we compared mathematical modeling data from OGTTs to those from a hyperglycemic clamp within the RISE Study. Modeled measures were the dose-response relationship between glucose and insulin secretion (glucose sensitivity [GS], rate sensitivity [RS]) and the oral glucose insulin sensitivity index (OGIS). Clamp measures were insulin sensitivity (steady state glucose infusion rate/insulin [M/I]), acute (0-10 minutes) C-peptide (ACPRg) and insulin (AIRg) responses to glucose, steady-state C-peptide (SSCP) at plasma glucose of 11.1 mmol/L, and arginine-stimulated maximum C-peptide (ACPRmax) response at glucose >25 mmol/L. Linear regression models were fit to assess relationships between OGTT model and clamp measures by age group. GS (r2 = 0.29, p2 = 0.22, p2 = 0.55, p2 = 0.52, p2 = 0.46, p2 = 0.33, p2 = 0.55, p2 = 0.34, p<0.01). The inverse correlation of GS with M/I in both Y and A suggests that differences in insulin sensitivity should be accounted for when comparing GS across groups. The fact that relationships between acute insulin and C-peptide responses from the clamp and GS and RS from OGTTs differed between Y and A, while these relationships were similar for SSCP and ACPRmax, suggest fundamental differences exist in the early-phase response between Y and A with IGT or early DM. Disclosure: K. Utzschneider: Consultant; Self; Novo Nordisk Inc. A. Mari: Consultant; Self; Eli Lilly and Company. Research Support; Self; Boehringer Ingelheim International GmbH. M. Tripputi: None. K.J. Mather: Advisory Panel; Self; Roche Diabetes Care. Research Support; Self; Abbott, Merck & Co., Inc., Novo Nordisk A/S, Sanofi. K.J. Nadeau: None. S. Edelstein: None. T.S. Hannon: Advisory Panel; Self; Eli Lilly and Company. S.A. Arslanian: None. M. Cree-Green: None. T.A. Buchanan: Research Support; Self; Allergan, Apollo EndoSurgery. S. Caprio: None. S.E. Kahn: Advisory Panel; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Intarcia Therapeutics, Inc., Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk A/S. Consultant; Self; Neurimmune. Other Relationship; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk A/S. R. Consortium: None. Funding: American Diabetes Association (1-14-RISE-01 to S.E.K.); National Institute of Diabetes and Digestive and Kidney Diseases
- Publication
Diabetes, 2019, Vol 68, pN.PAG
- ISSN
0012-1797
- Publication type
Academic Journal
- DOI
10.2337/db19-1826-P